India grants emergency use authorization to Covaxin for 6-12 age group, Corbevax for 5-12 age group

STORY: India grants emergency use authorization to Covaxin for 6-12 age group, Corbevax for 5-12 age group DATELINE: April 27, 2022 LENGTH: 00:01:32 LOCATION: New Delhi CATEGORY: HEALTH SHOTLIST: 1. STANDUP (English): DEEPAK PRAKASH, Xinhua reporter 2. various of street views of New Delhi 3. various of AIIMS (All India Institute Of Medical Science) hospital area 4. various of India's vaccination drive STORYLINE: STANDUP (English): DEEPAK PRAKASH, Xinhua reporter "The Drugs Controller General of India (DCGI) Tuesday granted emergency use authorization to Covaxin for children between 6-12 years and Corbevax for those between 5-12 years of age." The approval has come amid an uptick in the COVID-19 cases in schools. India is witnessing the surge in COVID-19 cases again at a time when markets have been reopened, businesses returned to normalcy and travel activities resumed to the pre-pandemic levels. Schools and colleges have been open for in-person classes and there is no bar to gatherings. The approval by t

BOTSWANA-GABORONE-COVID-19 VACCINE-MANUFACTURING PLANT-LAUNCH

BOTSWANA-GABORONE-COVID-19 VACCINE-MANUFACTURING PLANT-LAUNCH

(220329) -- GABORONE, March 29, 2022 (Xinhua) -- Botswana President Mokgweetsi Masisi (L) attends a ceremony for the launch of the NantBotswana vaccine manufacturing plant in Gaborone, Botswana, on March 28, 2022. The NantBotswana plant will produce Pula Corbevax vaccine against COVID-19 developed in partnership with Texas Children's Hospital Center for Vaccine Development and Baylor College of Medicine, said Masisi during the ceremony. (Photo by Tshekiso Tebalo/Xinhua)

BOTSWANA-GABORONE-COVID-19 VACCINE-MANUFACTURING PLANT-LAUNCH

BOTSWANA-GABORONE-COVID-19 VACCINE-MANUFACTURING PLANT-LAUNCH

(220329) -- GABORONE, March 29, 2022 (Xinhua) -- Botswana President Mokgweetsi Masisi (L) and Chief Executive Officer (CEO) of NantWorks Patrick Soon-Shiong, attend a ceremony for the launch of the NantBotswana vaccine manufacturing plant in Gaborone, Botswana, on March 28, 2022. The NantBotswana plant will produce Pula Corbevax vaccine against COVID-19 developed in partnership with Texas Children's Hospital Center for Vaccine Development and Baylor College of Medicine, said Masisi during the ceremony. (Photo by Tshekiso Tebalo/Xinhua)